Anti-OX40 (CD134) administration to nonhuman primates: Immunostimulatory effects and toxicokinetic study

Andrew D. Weinberg, Colin Thalhofer, Nick Morris, Joshua M. Walker, Donald Seiss, Scott Wong, Michael Axthelm, Louis Picker, Walter J. Urba

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The immune-stimulatory properties of anti-CD134 (OX40) antibodies have been well documented in rodents, including their ability to enhance antitumor immunity. In this study, an anti-OX40 antibody (Ab) known to costimulate monkey T cells in vitro, was infused into rhesus macaque monkeys during immunization with the simian immunodeficiency virus protein, gp130. The draining lymph nodes from immunized monkeys treated with anti-OX40 were enlarged compared with immunized monkeys injected with mouse Ig. Anti-OX40-treated monkeys had increased gp130-specific Ab titers, and increased long-lived T-cell responses, compared with controls. There were no overt signs of toxicity in the anti-OX40-treated monkeys. The encouraging immune-stimulatory effects led to the good manufacturing practice production of an anti-OX40 Ab for clinical trials in cancer patients. A detailed toxicology study was performed with anti-OX40 in nonhuman primates. Three groups of 8 monkeys received anti-OX40 at 1 of 3 dose levels (0.4, 2.0, and 10 mg/kg) and a control group received saline. No clinical toxicity was observed, but acute splenomegaly and enlarged gut-associated lymph nodes were observed in the anti-OX40-treated animals; splenomegaly and lymphadenopathy resolved by day 28. These studies demonstrate the immune-stimulatory properties and safety of anti-OX40 in primates and provide a strong scientific rationale to pursue clinical trials in humans.

Original languageEnglish (US)
Pages (from-to)575-585
Number of pages11
JournalJournal of Immunotherapy
Volume29
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

Primates
Haplorhini
Splenomegaly
Macaca mulatta
Anti-Idiotypic Antibodies
Lymph Nodes
Clinical Trials
T-Lymphocytes
Antibodies
Toxicology
Toxicokinetics
Immunity
Rodentia
Immunization
Safety
Control Groups
Neoplasms
Proteins

Keywords

  • Costimulation
  • Immunotherapy
  • T cells
  • TNF receptor family member

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Anti-OX40 (CD134) administration to nonhuman primates : Immunostimulatory effects and toxicokinetic study. / Weinberg, Andrew D.; Thalhofer, Colin; Morris, Nick; Walker, Joshua M.; Seiss, Donald; Wong, Scott; Axthelm, Michael; Picker, Louis; Urba, Walter J.

In: Journal of Immunotherapy, Vol. 29, No. 6, 11.2006, p. 575-585.

Research output: Contribution to journalArticle

Weinberg, Andrew D. ; Thalhofer, Colin ; Morris, Nick ; Walker, Joshua M. ; Seiss, Donald ; Wong, Scott ; Axthelm, Michael ; Picker, Louis ; Urba, Walter J. / Anti-OX40 (CD134) administration to nonhuman primates : Immunostimulatory effects and toxicokinetic study. In: Journal of Immunotherapy. 2006 ; Vol. 29, No. 6. pp. 575-585.
@article{bd1dd7373f8f4042bd5d6573ea1006bd,
title = "Anti-OX40 (CD134) administration to nonhuman primates: Immunostimulatory effects and toxicokinetic study",
abstract = "The immune-stimulatory properties of anti-CD134 (OX40) antibodies have been well documented in rodents, including their ability to enhance antitumor immunity. In this study, an anti-OX40 antibody (Ab) known to costimulate monkey T cells in vitro, was infused into rhesus macaque monkeys during immunization with the simian immunodeficiency virus protein, gp130. The draining lymph nodes from immunized monkeys treated with anti-OX40 were enlarged compared with immunized monkeys injected with mouse Ig. Anti-OX40-treated monkeys had increased gp130-specific Ab titers, and increased long-lived T-cell responses, compared with controls. There were no overt signs of toxicity in the anti-OX40-treated monkeys. The encouraging immune-stimulatory effects led to the good manufacturing practice production of an anti-OX40 Ab for clinical trials in cancer patients. A detailed toxicology study was performed with anti-OX40 in nonhuman primates. Three groups of 8 monkeys received anti-OX40 at 1 of 3 dose levels (0.4, 2.0, and 10 mg/kg) and a control group received saline. No clinical toxicity was observed, but acute splenomegaly and enlarged gut-associated lymph nodes were observed in the anti-OX40-treated animals; splenomegaly and lymphadenopathy resolved by day 28. These studies demonstrate the immune-stimulatory properties and safety of anti-OX40 in primates and provide a strong scientific rationale to pursue clinical trials in humans.",
keywords = "Costimulation, Immunotherapy, T cells, TNF receptor family member",
author = "Weinberg, {Andrew D.} and Colin Thalhofer and Nick Morris and Walker, {Joshua M.} and Donald Seiss and Scott Wong and Michael Axthelm and Louis Picker and Urba, {Walter J.}",
year = "2006",
month = "11",
doi = "10.1097/01.cji.0000211319.00031.fc",
language = "English (US)",
volume = "29",
pages = "575--585",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Anti-OX40 (CD134) administration to nonhuman primates

T2 - Immunostimulatory effects and toxicokinetic study

AU - Weinberg, Andrew D.

AU - Thalhofer, Colin

AU - Morris, Nick

AU - Walker, Joshua M.

AU - Seiss, Donald

AU - Wong, Scott

AU - Axthelm, Michael

AU - Picker, Louis

AU - Urba, Walter J.

PY - 2006/11

Y1 - 2006/11

N2 - The immune-stimulatory properties of anti-CD134 (OX40) antibodies have been well documented in rodents, including their ability to enhance antitumor immunity. In this study, an anti-OX40 antibody (Ab) known to costimulate monkey T cells in vitro, was infused into rhesus macaque monkeys during immunization with the simian immunodeficiency virus protein, gp130. The draining lymph nodes from immunized monkeys treated with anti-OX40 were enlarged compared with immunized monkeys injected with mouse Ig. Anti-OX40-treated monkeys had increased gp130-specific Ab titers, and increased long-lived T-cell responses, compared with controls. There were no overt signs of toxicity in the anti-OX40-treated monkeys. The encouraging immune-stimulatory effects led to the good manufacturing practice production of an anti-OX40 Ab for clinical trials in cancer patients. A detailed toxicology study was performed with anti-OX40 in nonhuman primates. Three groups of 8 monkeys received anti-OX40 at 1 of 3 dose levels (0.4, 2.0, and 10 mg/kg) and a control group received saline. No clinical toxicity was observed, but acute splenomegaly and enlarged gut-associated lymph nodes were observed in the anti-OX40-treated animals; splenomegaly and lymphadenopathy resolved by day 28. These studies demonstrate the immune-stimulatory properties and safety of anti-OX40 in primates and provide a strong scientific rationale to pursue clinical trials in humans.

AB - The immune-stimulatory properties of anti-CD134 (OX40) antibodies have been well documented in rodents, including their ability to enhance antitumor immunity. In this study, an anti-OX40 antibody (Ab) known to costimulate monkey T cells in vitro, was infused into rhesus macaque monkeys during immunization with the simian immunodeficiency virus protein, gp130. The draining lymph nodes from immunized monkeys treated with anti-OX40 were enlarged compared with immunized monkeys injected with mouse Ig. Anti-OX40-treated monkeys had increased gp130-specific Ab titers, and increased long-lived T-cell responses, compared with controls. There were no overt signs of toxicity in the anti-OX40-treated monkeys. The encouraging immune-stimulatory effects led to the good manufacturing practice production of an anti-OX40 Ab for clinical trials in cancer patients. A detailed toxicology study was performed with anti-OX40 in nonhuman primates. Three groups of 8 monkeys received anti-OX40 at 1 of 3 dose levels (0.4, 2.0, and 10 mg/kg) and a control group received saline. No clinical toxicity was observed, but acute splenomegaly and enlarged gut-associated lymph nodes were observed in the anti-OX40-treated animals; splenomegaly and lymphadenopathy resolved by day 28. These studies demonstrate the immune-stimulatory properties and safety of anti-OX40 in primates and provide a strong scientific rationale to pursue clinical trials in humans.

KW - Costimulation

KW - Immunotherapy

KW - T cells

KW - TNF receptor family member

UR - http://www.scopus.com/inward/record.url?scp=33750546487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750546487&partnerID=8YFLogxK

U2 - 10.1097/01.cji.0000211319.00031.fc

DO - 10.1097/01.cji.0000211319.00031.fc

M3 - Article

C2 - 17063120

AN - SCOPUS:33750546487

VL - 29

SP - 575

EP - 585

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -